# Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease

> **NCT05510115** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Colorado, Denver** · enrollment: 50 (estimated)

## Conditions studied

- Polycystic Kidney, Autosomal Dominant

## Interventions

- **DRUG:** Empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05510115
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-18
- **Primary completion:** 2026-03-18
- **Final completion:** 2026-08-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-05-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05510115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05510115, "Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05510115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*